PLRX
Income statement / Annual
Last year (2023), Pliant Therapeutics, Inc.'s total revenue was $1.58 M,
a decrease of 83.69% from the previous year.
In 2023, Pliant Therapeutics, Inc.'s net income was -$161.34 M.
See Pliant Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$1.58 M
|
$9.69 M
|
$7.57 M
|
$41.82 M
|
$57.05 M
|
$0.00
|
$0.00
|
| Cost of Revenue |
$1.84 M |
$3.68 M |
$3.20 M |
$0.00 |
$0.00 |
$666,000.00 |
$0.00 |
| Gross Profit |
-$261,000.00 |
$6.00 M |
$4.37 M |
$41.82 M |
$57.05 M |
-$666,000.00 |
$0.00 |
| Gross Profit Ratio |
-0.17 |
0.62 |
0.58 |
1 |
1 |
0 |
0 |
| Research and Development
Expenses |
$127.80 M
|
$96.94 M
|
$77.55 M
|
$66.19 M
|
$47.35 M
|
$24.42 M
|
$14.53 M
|
| General & Administrative
Expenses |
$57.93 M
|
$39.95 M
|
$27.56 M
|
$17.27 M
|
$10.93 M
|
$6.50 M
|
$3.82 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$57.93 M
|
$39.95 M
|
$27.56 M
|
$17.27 M
|
$10.93 M
|
$6.50 M
|
$3.82 M
|
| Other Expenses |
$0.00 |
$0.00 |
-$77.55 M |
-$366,000.00 |
-$216,000.00 |
-$49,000.00 |
$0.00 |
| Operating Expenses |
$185.73 M |
$136.89 M |
$27.56 M |
$83.46 M |
$58.28 M |
$30.92 M |
$18.35 M |
| Cost And Expenses |
$185.73 M |
$136.89 M |
$27.56 M |
$83.46 M |
$58.28 M |
$30.92 M |
$18.35 M |
| Interest Income |
$24.08 M |
$4.67 M |
$272,000.00 |
$478,000.00 |
$816,000.00 |
$688,000.00 |
$16,000.00 |
| Interest Expense |
$1.27 M |
$791,000.00 |
$272,000.00 |
$366,000.00 |
$216,000.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$1.84 M
|
$3.68 M
|
$3.20 M
|
$1.31 M
|
$1.11 M
|
$666,000.00
|
$292,000.00
|
| EBITDA |
-$158.23 M
|
-$118.85 M
|
-$95.73 M
|
-$40.34 M
|
-$118,000.00
|
-$30.25 M
|
-$18.06 M
|
| EBITDA Ratio |
-100.14 |
-12.65 |
-2.64 |
-1 |
-0 |
0 |
0 |
| Operating Income Ratio
|
-116.55
|
-13.13
|
-2.64
|
-1
|
-0.02
|
0
|
0
|
| Total Other
Income/Expenses Net |
$22.81 M
|
$3.88 M
|
$272,000.00
|
$112,000.00
|
$600,000.00
|
$639,000.00
|
$16,000.00
|
| Income Before Tax |
-$161.34 M |
-$123.32 M |
-$19.71 M |
-$41.53 M |
-$631,000.00 |
-$30.28 M |
-$18.33 M |
| Income Before Tax Ratio
|
-102.11
|
-12.73
|
-2.6
|
-0.99
|
-0.01
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$1.82 M |
-$1.81 M |
-$1.79 M |
-$816,000.00 |
$639,000.00 |
$2.29 M |
| Net Income |
-$161.34 M |
-$121.50 M |
-$17.91 M |
-$39.75 M |
$185,000.00 |
-$30.28 M |
-$20.62 M |
| Net Income Ratio |
-102.11 |
-12.54 |
-2.36 |
-0.95 |
0 |
0 |
0 |
| EPS |
-2.75 |
-2.89 |
-0.5 |
-1.12 |
0.0052 |
-1.83 |
-25.67 |
| EPS Diluted |
-2.75 |
-2.89 |
-0.5 |
-1.12 |
0.0052 |
-1.83 |
-25.67 |
| Weighted Average Shares
Out |
$58.72 M
|
$42.02 M
|
$35.85 M
|
$35.55 M
|
$35.55 M
|
$16.51 M
|
$803,497.00
|
| Weighted Average Shares
Out Diluted |
$58.72 M
|
$42.02 M
|
$35.85 M
|
$35.55 M
|
$35.55 M
|
$16.51 M
|
$803,497.00
|
| Link |
|
|
|
|
|
|
|
